Advanced Soft-tissue Sarcoma Clinical Trial
Official title:
A Phase 1b, Open-label, Dose-escalation Clinical Study Evaluating the Safety of Camsirubicin With Prophylactic Pegfilgrastim in the Treatment of Advanced Soft Tissue Sarcomas
This is an Interventional Study in Advanced Soft Tissue Sarcomas (ASTS). It is a Phase 1b, open-label, dose-escalation clinical study evaluating the safety of camsirubicin with prophylactic pegfilgrastim in the treatment of advanced soft tissue sarcomas. The objective of the study is to evaluate the safety of camsirubicin with prophylactic pegfilgrastim in the treatment of ASTS and determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of camsirubicin with prophylactic pegfilgrastim. The primary endpoint is the MTD (RP2D).The secondary endpoints are: safety profile of camsirubicin with prophylactic pegfilgrastim, PFS, TTP, ORR, DoR, OS and PK. As exploratory endpoint, Quality of life will be measured by using the Functional Assessment of Cancer Therapy: General (FACT-G).
Status | Recruiting |
Enrollment | 21 |
Est. completion date | June 2025 |
Est. primary completion date | June 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Patients must meet all of the following criteria to be eligible for inclusion in this study: 1. The participant must provide written informed consent prior to performance of study-specific procedures and must be willing to comply with treatment and follow-up. Informed consent must be obtained prior to start of the screening process. Procedures conducted as part of the patient's routine clinical management (e.g., blood count, imaging tests) and obtained prior to signature of informed consent may be used for screening or baseline purposes as long as these procedures are conducted as specified in the protocol. 2. Age =18 years. 3. Only locally confirmed histological diagnosis of advanced unresectable or metastatic malignant soft tissue sarcoma (including leiomyosarcoma, dedifferentiated liposarcoma, myxoid liposarcoma, pleomorphic liposarcoma, undifferentiated pleomorphic sarcoma, malignant peripheral nerve sheath tumor, high-grade sarcoma [not otherwise specified], or synovial sarcoma) not amenable to curative treatment with surgery or radiotherapy. 4. Presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). 5. Performance status 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale. 6. The participant has not received any previous treatment with anthracyclines (not even in adjuvant therapy). 7. The participant has not had any prior systemic cytotoxic therapies for advanced/metastatic sarcoma and is considered an appropriate candidate for anthracycline therapy. All previous anticancer treatments must be completed =28 days prior to first dose of study drug. 8. Laboratory tests must be as follows and may be repeated once at the discretion of the investigator: 1. Absolute neutrophil count (ANC) =1,500/mm³ 2. Platelet count =100,000/mm³ 3. Hemoglobin >9 g/dL 4. Bilirubin <1.5 times upper limit of normal (ULN); except subjects with Gilbert Syndrome who must have a total bilirubin level <3.0 x ULN 5. Prothrombin time (PT) (seconds) or international normalized ratio (INR) =1.5 x ULN 6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 x ULN or, in patients with documented hepatic metastasis, =5 x ULN 7. Serum creatinine =1.5 mg/dL or estimated creatinine clearance =60 mL/min (Cockroft and Gault) 9. Left ventricular ejection fraction (LVEF) =50% assessed within 28 days prior to enrollment. 10. Females of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to enrollment. A female is eligible to enter and participate in the study if she is of non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had a hysterectomy, a bilateral oophorectomy (ovariectomy), a bilateral tubal ligation, or is postmenopausal with a minimum of 1 year without menses. 11. Both males and females must agree to use highly effective contraceptive precautions if conception is possible during the dosing period and up to 3 months following the last dose of study drug. 12. Female patients who are lactating must agree to discontinue nursing prior to the first dose of study drug and must refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug. 13. The participant has, in the opinion of the investigator, a life expectancy of at least 3 months. Exclusion Criteria: Patients must not meet any of the exclusion criteria to be eligible for study participation. 1. Current evidence/diagnosis of alveolar soft part sarcoma, extraskeletal myxoid chondrosarcoma, rhabdomyosarcoma, osteosarcoma, gastrointestinal stromal tumor (GIST), dermatofibrosarcoma (unless transformed to fibrosarcoma), Ewing's sarcoma, Kaposi's sarcoma, mixed mesodermal tumor, or clear cell sarcomas. 2. Patients who cannot tolerate pegfilgrastim. 3. Known active central nervous system (CNS) or leptomeningeal metastasis (brain metastasis) at the time of enrollment. Participants with a history of a CNS metastasis previously treated with curative intent (e.g., stereotactic radiation or surgery) that have not progressed on follow-up imaging, have been asymptomatic for at least 60 days prior to first dose, and are not receiving systemic corticosteroids and or/anticonvulsants are eligible. Participants with signs or symptoms of neurological compromise should have appropriate radiographic imaging performed before enrollment to rule out brain metastasis. 4. Prior treatment with doxorubicin, epirubicin, idarubicin, and/or other anthracyclines or anthracenediones (including adjuvant therapy). 5. Prior radiotherapy of the mediastinal/pericardial area or whole pelvis radiation. Other thoracic radiotherapy is permitted. 6. The participant has symptomatic congestive heart failure (CHF), left ventricular ejection fraction dysfunction (LVEF <50%), severe myocardial insufficiency, cardiac arrhythmia (uncontrolled, clinically significant), or cardiomyopathy. 7. The participant has unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction within 6 months of enrollment. 8. The participant has a QT interval calculated using Fridericia's correction (QTcF) of >450 milliseconds (msec) for males and >470 msec for females on screening electrocardiogram (ECG). 9. Females who are pregnant or breastfeeding. 10. Known allergy to any of the treatment components including a history of allergic reactions attributed to compounds of chemical or biological composition similar to doxorubicin and camsirubicin, including intravenous (IV) lactose, or pegfilgrastim. 11. The participant has a known, uncontrolled active fungal, uncontrolled bacterial, or uncontrolled viral infection including human immunodeficiency virus (HIV) or viral hepatitis (B or C). 12. Any malignancy other than soft tissue sarcoma within the last 5 years prior to screening, with the exception of: 1. Cervical carcinoma in situ or 2. Basal cell carcinoma or 3. Superficial bladder tumors that have been successfully and curatively treated with no evidence of recurrent or residual disease. 13. Unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, confound the assessment of camsirubicin's effect, jeopardize the safety of a patient and/or their compliance with the protocol. 14. Currently receiving any investigational agents. |
Country | Name | City | State |
---|---|---|---|
United States | Sarcoma Oncology Center | Santa Monica | California |
United States | University of Washington Medicine Fred Hutchinson Cancer Center | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Monopar Therapeutics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine Maximum Tolerated Dose (MTD) | Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0) will be collected for all treated subjects at each dose level of camsirubicin to identify dose limiting toxicities (DLTs). At each successive dose level, cohorts of 3 new patients will be entered if no dose limiting toxicity (DLT) is observed (3+3 design) within 21 days of initial dose. If a patient treated at any dose level experiences a DLT, a total of up to 6 patients will be treated at that dose level. Once two patients at any dose level experience a DLT, no additional patients will be treated at that level. The MTD will be defined as the highest dose level below the dose level at which 2 or more patients experience a DLT during the first 21 days from Cycle 1 Day 1. | 3 weeks after first injection | |
Primary | Recommended Phase 2 Dose (RP2D) Camsirubicin HCl for Injection | The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for the safety expansion cohort, based on safety, tolerability, efficacy, PK, and MTD data collected during the dose escalation portion of the study. | Up to 1 year after the first dose | |
Secondary | Incidence of Treatment-Emergent Adverse Events [Safety] | Safety profile of camsirubicin with prophylactic pegfilgrastim, through assessment of adverse event (AE) type, incidence, severity, time of appearance, and related causes (detected by physical explorations and laboratory tests). Adverse events will be graded and tabulated using NCI CTCAE v5.0. | Up to 1 year after the first dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05146440 -
Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination With Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor
|
Phase 1/Phase 2 | |
Recruiting |
NCT05620693 -
Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma
|
N/A | |
Recruiting |
NCT05809830 -
Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06367075 -
A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT04874311 -
Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma
|
Phase 2 | |
Recruiting |
NCT05876715 -
LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04757337 -
Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients
|
Phase 3 | |
Recruiting |
NCT04705818 -
Combining Epigenetic And Immune Therapy to Beat Cancer.
|
Phase 2 | |
Terminated |
NCT05154630 -
Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05099666 -
Lurbinectedin + Doxorubicin In Leiomyosarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT03022448 -
Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS)
|
||
Recruiting |
NCT04204941 -
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
|
Phase 3 | |
Recruiting |
NCT05182164 -
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
|
Phase 2 | |
Recruiting |
NCT05180695 -
HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
|
Phase 1/Phase 2 | |
Terminated |
NCT04780464 -
A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma
|
Phase 3 |